Healthcare Regulation (HIPAA)

A new AI tool is shifting post-acute care from relationship-based referrals to data-driven strategy by analyzing entire physician groups, not just doctors.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

The online therapy market is booming, attracting institutional capital. We dissect the growth drivers, regulatory risks, and evolving business models.

With air quality plummeting, a new wellness market is booming. We investigate the science and business behind lung health supplements for wildfire season.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

An AI named Grace is now collecting hospital bills more effectively and with higher patient satisfaction than humans. Is this the future of service or a step too far?

A new partnership between AI consultancy Toboggan Labs and research giant Mila aims to solve a critical problem: turning cutting-edge AI into real-world medical tools.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

One company's focus on convenience just earned it top marks. We explore how streamlined ordering and tech-savvy verification are reshaping the vision care industry.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

A major data breach at Ohio Living exposes sensitive patient and employee data, echoing a past failure and signaling a deepening crisis for the entire sector.

A Chicago jury's landmark verdict reveals how a single day's delay can lead to a lifetime of paralysis, questioning the very fabric of patient safety.